Transcutaneous Electrical Acustimulation to Help Postoperative Bowel Function after Colorectal Cancer Surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study enrolls patients aged 65 and older undergoing minimally invasive colorectal cancer surgery to receive transcutaneous electrical acustimulation or a non-acupoint sham treatment for three days starting the day after surgery. Researchers will track time to first defecation, defecation events, and resumption of eating, along with any adverse effects. The trial aims to determine if TEA improves postoperative intestinal recovery and reduces complications related to bowel function. Participants are monitored for safety, and data will be compared between the TEA and sham groups. The study is conducted at two Chinese hospitals with the lead sponsor being Sir Run Run Shaw Hospital.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 65 years old.
* Elective minimally invasive (laparoscopic or robotic) resection of colorectal cancer.
* American Society of Anesthesiologists classification (ASA) 1-4.
* Able to understand the research process and the use of various assessment scales, and able to communicate effectively with the researchers.
* The patient voluntarily participates in this study and signs the informed consent form.

Exclusion Criteria:

* Previous history of abdominal gastrointestinal surgery.
* Planned for palliative or emergency surgery.
* Planned for open abdominal surgery or creation of a new stoma.
* Transfer to ICU.
* Diagnosed with severe heart, liver, kidney or mental system diseases.
* Patients with implanted cardiac pacemakers.
* Patients currently using or having used in the past month glucagon-like peptide-1 (GLP-1) receptor agonists, dual glucose-dependent insulinotropic polypeptide (GIP) receptor agonists, and sodium-glucose cotransporter-2 (SGLT-2) inhibitors.
* Planned to use epidural anesthesia or epidural analgesia.
* Presence of local skin lesions, infection at the stimulation site, or obvious skin allergy or severe skin sensitivity to electrodes/adhesive materials.
* Participated in other clinical studies within the past 3 months or received acupuncture treatment within the past month.
* Other conditions that the investigator considers make the patient unsuitable for participation in this study.

Where it's running

• Sir Run Run Shaw Hospital
  Hangzhou, Zhejiang, China Recruiting
• Shandong Medical and Pharmaceutical University Hospital
  Binzhou, Shandong, China Not yet recruiting

Study contacts

• Study coordinator: Xin Yu
• Email: xinxin_yu@zju.edu.cn
• Phone: 86006663

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Toripalimab Plus Cetuximab and Irinotecan for second-line right-sided colon cancer

  This phase II study tests whether a combo of toripalimab, cetuximab, and irinotecan helps adults with second-line, right‑sided, RAS/BRAF wild-type advanced colon cancer.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT07896681

• Intratumoral oncolytic virus plus immune checkpoint inhibitors in metastatic colorectal, gastric, or liver cancer

  Doctors are testing whether injecting an oncolytic virus directly into tumors along with immune checkpoint drugs is safe and may help people with advanced colorectal, gastric, or liver cancer who have tried many treatments.

  Recruiting Foshan Fosun Chancheng Hospital · Guangdong, Foshan · NCT07850882

• Targeted alpha-radiation therapy for NTSR1-positive tumors using SKL35501/SKL35502

  This early-phase trial tests whether a two-part approach—an imaging agent to find NTSR1-expressing tumors and a targeted alpha-ray therapy—can be safely used in adults with certain advanced solid tumors.

  Recruiting Phase 1 SK Life Science, Inc. · Glen Burnie, Maryland and 4 other locations · NCT07812805

• Pirfenidone plus PD-1 inhibitor with or without targeted radiotherapy for advanced colorectal cancer

  This study tests whether combining pirfenidone with a PD-1 inhibitor, with or without hypofractionated radiotherapy, is safe and helps people with unresectable or metastatic pMMR/MSS colorectal cancer who have exhausted standard therapies.

  Recruiting Phase 2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07644286

• VMD-102 in liver cancer and other solid tumors

  This study tests VMD-102 to see if it is safe and tolerable and to find the best dose for further study in adults with advanced liver cancer and several other solid tumors.

  Recruiting at 2 sites Phase 1/2 VM Discovery, Inc. · Scottsdale, Arizona and 1 other locations · NCT07636785

• First-in-human imaging study of 68Ga-DFC413 and comparison with 68Ga-NNS309 in solid tumors

  This study tests a new radioactive imaging agent, 68Ga-DFC413, to see how it behaves in patients with several solid tumors and compares it to 68Ga-NNS309.

  Recruiting at 2 sites Phase 1 Novartis · Odense C and 1 other locations · NCT07630961

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.